B J Allen

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. pmc Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Centre, Gray St, Kogarah, NSW 2217, Australia
    Br J Cancer 88:944-50. 2003
  2. pmc MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
    C F Qu
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St Kogarah, NSW 2217, Australia
    Br J Cancer 91:2086-93. 2004
  3. pmc 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
    Y Li
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, NSW, Australia
    Br J Cancer 86:1197-203. 2002
  4. ncbi request reprint Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah, New South Wales, Australia
    Australas Radiol 43:480-6. 1999
  5. ncbi request reprint Production of terbium-152 by heavy ion reactions and proton induced spallation
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah, NSW, Australia
    Appl Radiat Isot 54:53-8. 2001
  6. ncbi request reprint Preclinical targeted alpha therapy for subcutaneous melanoma
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray St Kogarah, Australia
    Melanoma Res 11:175-82. 2001
  7. ncbi request reprint In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray Street, Kogarah NSW 2219, Australia
    Crit Rev Oncol Hematol 39:139-46. 2001
  8. ncbi request reprint Intralesional targeted alpha therapy for metastatic melanoma
    Barry J Allen
    Centre for Experimental Radiation Oncology, St George Hospital, Kogarah, NSW 2217, Australia
    Cancer Biol Ther 4:1318-24. 2005
  9. ncbi request reprint In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen
    Y Li
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
    Prostate Cancer Prostatic Dis 5:36-46. 2002
  10. ncbi request reprint In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells
    M Ranson
    Department of Biological Science, University of Wollongong, Kogarah, NSW, Australia
    Breast Cancer Res Treat 71:149-59. 2002

Collaborators

Detail Information

Publications40

  1. pmc Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Centre, Gray St, Kogarah, NSW 2217, Australia
    Br J Cancer 88:944-50. 2003
    ..Thus, (213)Bi-PAI2 is successful in targeting isolated breast cancer cells and preangiogenic cell clusters. These results indicate the promising potential of (213)Bi-PAI2 as a novel therapeutic agent for micrometastatic breast cancer...
  2. pmc MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
    C F Qu
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St Kogarah, NSW 2217, Australia
    Br J Cancer 91:2086-93. 2004
    ..213)Bi-C595 may be a useful agent for the treatment of micrometastases or minimal residual disease (MRD) in pancreatic cancer patients with overexpression of MUC1 antigen...
  3. pmc 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
    Y Li
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, NSW, Australia
    Br J Cancer 86:1197-203. 2002
    ....
  4. ncbi request reprint Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah, New South Wales, Australia
    Australas Radiol 43:480-6. 1999
    ..The ready and low-cost availability of the Ac:Bi generator is an important element in the implementation of clinical trials for patients with poor prognoses but without evidence of metastatic disease...
  5. ncbi request reprint Production of terbium-152 by heavy ion reactions and proton induced spallation
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah, NSW, Australia
    Appl Radiat Isot 54:53-8. 2001
    ..However, the current availability of this radioisotope will be restricted to major nuclear physics research centres...
  6. ncbi request reprint Preclinical targeted alpha therapy for subcutaneous melanoma
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray St Kogarah, Australia
    Melanoma Res 11:175-82. 2001
    ..Systemic TAT was less effective, with all tumours experiencing growth delay and limited inhibition of tumour growth. These data provide the basis for clinical trials of TAT in recurrent subcutaneous melanoma...
  7. ncbi request reprint In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray Street, Kogarah NSW 2219, Australia
    Crit Rev Oncol Hematol 39:139-46. 2001
    ..Intra-lesional TAT of established melanoma showed that all melanomas regressed with 100 microCi injections of AIC. These results point to the potential application of local and systemic TAT in the management of metastatic cancer...
  8. ncbi request reprint Intralesional targeted alpha therapy for metastatic melanoma
    Barry J Allen
    Centre for Experimental Radiation Oncology, St George Hospital, Kogarah, NSW 2217, Australia
    Cancer Biol Ther 4:1318-24. 2005
    ..This paper reports the development and application of intralesional targeted alpha therapy (TAT) for melanoma, being the first part of a program to establish a new systemic therapy...
  9. ncbi request reprint In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen
    Y Li
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
    Prostate Cancer Prostatic Dis 5:36-46. 2002
    ..Because of its in vitro cytotoxicity and these anti-proliferative properties in vivo, the (213)Bi-J591 conjugate has considerable potential as a new therapeutic agent for the treatment of prostate cancer...
  10. ncbi request reprint In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells
    M Ranson
    Department of Biological Science, University of Wollongong, Kogarah, NSW, Australia
    Breast Cancer Res Treat 71:149-59. 2002
    ..In conclusion, we have validated, in vitro, the potential of alpha-PAI-2 as a novel therapeutic agent for breast cancer...
  11. ncbi request reprint Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
    G Melville
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray Street, Kogarah, NSW 2217, Australia
    Appl Radiat Isot 65:1014-22. 2007
    ..A more powerful linac is required that runs at a higher current, longer pulse length and higher frequency for practical production. This process could also lead to the reduction of the nuclear waste product Ra-226...
  12. pmc Selective uptake of boronated low-density lipoprotein in melanoma xenografts achieved by diet supplementation
    Y Setiawan
    Department of Pharmacy, University of Sydney, NSW, Australia
    Br J Cancer 74:1705-8. 1996
    ....
  13. ncbi request reprint In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes
    Syed M Abbas Rizvi
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray St, NSW 2217, Kogarah, Australia
    Leuk Res 26:37-43. 2002
    ..The high stability and outstanding cytotoxicity of the 213Bi conjugate provides the basis for targeted alpha therapy for the control of metastatic and disseminated cancer such as AML...
  14. ncbi request reprint Estimation of lean body weight in older women with hip fracture
    S J Mitchell
    S J Mitchell, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
    J Nutr Health Aging 16:188-92. 2012
    ..The aim of this study was to determine the ability of the LBW equation to estimate dual energy x-ray absorptiometry-derived fat free mass (FFM(DXA)) in a population of older women with recent hip fracture...
  15. pmc Human uveal melanoma expresses NG2 immunoreactivity
    Y Li
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray Street, Kogarah, NSW, Australia
    Br J Ophthalmol 87:629-32. 2003
    ..The purpose of this study was to evaluate the expression of NG2 immunoreactivity in human uveal melanoma and normal ocular tissue using mAb 9.2.27...
  16. ncbi request reprint Body composition of Aboriginal Australian women: comparison with age-matched Caucasians
    C Raja
    CERO, Cancer Care Centre, St George Hospital, Sydney, Australia
    Acta Diabetol 40:S314-6. 2003
    ..Key findings are that dual-energy X-ray absorptiometry can accurately assess adiposity, and that hip girth should emerge as a valid predictor of central adiposity, in AA women...
  17. ncbi request reprint In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength
    D Shahbazi-Gahrouei
    Centre for Experimental Radiation Oncology, University of Western Sydney, Nepean, New South Wales, Australia
    Australas Radiol 45:298-304. 2001
    ..5 mmol/L. For concentrations of more than 4 mmol/L in aqueous solutions of Gd-DTPA, 1 mmol/L in blood and 1.5 mmol/L in melanoma, signal intensity decreased with increased Gd-DTPA concentration...
  18. ncbi request reprint A theoretical model for the production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
    G Melville
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray St Kogarah, NSW, Australia
    Appl Radiat Isot 64:979-88. 2006
    ..However, a high power linac with high current, pulse length and frequency is needed to produce practical amounts of Ac-225 and a useful reduction of Ra-226...
  19. ncbi request reprint Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates
    Jian Wang
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, New South Wales, Australia
    Prostate 66:1753-67. 2006
    ..Our study investigated the therapeutic potential of multiple targeted alpha-therapy (MTAT) in the treatment of CaP micrometastases (spheroids) using (213)Bi-labeled multiple targeted alpha-radioimmunoconjugates...
  20. ncbi request reprint Addendum to: Basic immunology of antibody targeted radiotherapy: in regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8-S14)
    Barry J Allen
    Int J Radiat Oncol Biol Phys 68:314. 2007
  21. ncbi request reprint Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
    Chand Raja
    CERO, St George Hospital, Kogarah, Australia
    Cancer Biol Ther 6:846-52. 2007
    ..The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma...
  22. ncbi request reprint Targeted alpha-therapy for control of micrometastatic prostate cancer
    Yong Li
    St George Hospital, Immunology and Cell Biology, Center for Experimental Radiation Oncology, Cancer Care Center, Gray Street, Kogarah, NSW 2217, Australia
    Expert Rev Anticancer Ther 4:459-68. 2004
    ..This review will consider alpha-emitting radionuclides and current in vitro and in vivo studies with alpha-radioconjugates, and will focus on cell-surface target antigens and targeting vectors for the treatment of prostate cancer...
  23. ncbi request reprint Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer
    Emma Y Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, Australia
    Cancer Biol Ther 6:898-904. 2007
    ....
  24. ncbi request reprint Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer
    Barry J Allen
    Phys Med Biol 52:L15-9. 2007
    ..This effect depends on the expression of targeted receptors by capillary pericytes and contiguous cancer cells, and on the short-range and high-energy transfer of alpha radiation...
  25. ncbi request reprint Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
    Emma Y Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, UK
    Cancer Biol Ther 7:76-80. 2008
    ..The aim of this study was to investigate the effect of targeted alpha therapy (TAT) for the control of ascites in an OC ascites mouse model; the biodistribution of (213)Bi-C595 and its long term toxicity...
  26. ncbi request reprint Clinical trials of targeted alpha therapy for cancer
    Barry J Allen
    Centre for Experimental Radiation Oncology, St George Hospital, Gray St Kogarah NSW 2217, Australia
    Rev Recent Clin Trials 3:185-91. 2008
    ..Results of past and current trials are reviewed, and the bases of some proposed trials are presented...
  27. ncbi request reprint Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model
    Syed M Abbas Rizvi
    Center for Experimental Radiation Oncology CERO, Division of Cancer Services, St George Hospital, Gray Street, Kogarah, NSW 2217, Australia
    Cancer Biol Ther 5:386-93. 2006
    ..Targeted alpha therapy (TAT) is an experimental therapeutic modality for cancer. Another objective was to compare the in vivo pharmacokinetics using two different chelators to form the radioisotope-protein construct...
  28. ncbi request reprint Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer
    Chang F Qu
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
    Clin Exp Metastasis 22:575-86. 2005
    ..We have labeled PAI2 with (213)Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy...
  29. ncbi request reprint Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate
    Yong Li
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    Cancer Lett 205:161-71. 2004
    ..Our results suggest that 213Bi-Herceptin alpha-conjugate might be a promising new agent for the treatment of preangiogenic cancer cell clusters or micro-metastases with high levels of HER-2 expression...
  30. ncbi request reprint Targeted alpha therapy for cancer
    Barry J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah 2217, NSW, Australia
    Phys Med Biol 49:3703-12. 2004
    ..Results of the phase 1 clinical trial of TAT of subcutaneous, secondary melanoma indicate proof of the principle that TAT can make tumours in patients regress...
  31. ncbi request reprint Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates
    Yong Li
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray Street, Kogarah, NSW 2217, Australia
    Int J Radiat Oncol Biol Phys 60:896-908. 2004
    ..Some 30% of patients with clinically localized CaP will develop micrometastatic disease. Defining the expression of tumor-associated antigens on CaP will enable appropriate selection of therapeutic targets...
  32. ncbi request reprint Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate
    David Y Zhang
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW 2217, Australia
    Cancer Lett 218:181-90. 2005
    ..These results suggest that (231)Bi-Herceptin AC could be a novel agent for the treatment of breast cancer cell clusters or micro-metastases with high levels of HER2 expression...
  33. ncbi request reprint Targeted alpha therapy of prostate cancer
    Barry J Allen
    Center for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, Australia
    Methods Mol Med 81:333-57. 2003
  34. ncbi request reprint In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27
    Syed M Abbas Rizvi
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Kogarah, Sydney, NSW, Australia
    Cancer Biol Ther 4:763-8. 2005
    ..Key objectives of the study were to determine the pharmacokinetics and efficacy of the alpha emitting Bismuth-213 labeled 9.2.27 alpha-immunoconjugate (AIC)...
  35. ncbi request reprint In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595
    Chang F Qu
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, New South Wales, Australia
    Cancer Biol Ther 4:848-53. 2005
    ..The aim of this study was to investigate the effect of targeted alpha therapy for the control of in vitro pancreatic cancer cell clusters and micrometastatic cancer lesions in vivo...
  36. ncbi request reprint In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells
    Yong Li
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
    Invest Ophthalmol Vis Sci 46:4365-71. 2005
    ..2.27 and subsequently to assess the in vitro specificity and cytotoxicity of mAb 9.2.27 conjugated to the alpha-particle-emitting radioisotope 213bismuth (213Bi-9.2.27) for uveal melanoma cells...
  37. ncbi request reprint Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters
    Yan J Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    Cancer Lett 234:176-83. 2006
    ..These ACs are potential candidates for the control of ovarian cancer at the minimum residual disease (MRD) stage...
  38. doi request reprint The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy
    Emma Y Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, 2217 Kogarah, Australia
    Phys Med Biol 53:319-28. 2008
    ..The mean photon equivalent dose (PED) is 0.43 Gy (SD 0.15) and the mean MIRD calculated absorbed dose is 0.11 Gy (SD 0.03), giving an RBE=4+/-0.4 for this study...
  39. doi request reprint Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma
    Aiqun Xue
    Department of Surgery, The University of Sydney, Sydney, Australia
    Pancreas 36:160-7. 2008
    ..To determine the diagnostic and prognostic significance of growth factors and the urokinase-type plasminogen activator (uPA) system in pancreatic ductal adenocarcinoma (PDAC) using a multigene assay...
  40. ncbi request reprint MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer
    Paul J Cozzi
    Department of Surgery, St George Hospital, Kogarah, NSW, Australia
    Clin Exp Metastasis 22:565-73. 2005
    ..This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial...